



(51) International Patent Classification:

C07D 211/86 (2006.01) **C07D 413/12** (2006.01)
C07D 211/90 (2006.01) **C07D 417/04** (2006.01)
C07D 401/04 (2006.01) **C07D 417/14** (2006.01)
C07D 401/10 (2006.01) **C07F 9/40** (2006.01)
C07D 401/12 (2006.01) **A61K 31/4418** (2006.01)
C07D 401/14 (2006.01) **A61K 31/4427** (2006.01)
C07D 407/14 (2006.01) **A61P 3/00** (2006.01)
C07D 413/04 (2006.01)

(21) International Application Number:

PCT/US2012/067173

(22) International Filing Date:

30 November 2012 (30.11.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:


61/566,039 2 December 2011 (02.12.2011) US
 13/688,584 29 November 2012 (29.11.2012) US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**
 [US/US]; P.O. Box 4000, Route 206 and ProvinceLine
 Road, Princeton, New Jersey 08543-4000 (US).

(72) Inventors: **TURDI, Huji**; c/o Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534 (US). **HANGELAND, Jon J.**; c/o Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534 (US). **LAWRENCE, R. Michael**; c/o Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534 (US). **CHENG, Dong**; c/o Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534 (US). **AHMAD, Saleem**; c/o Bristol-Myers Squibb Company, Route 206 & Province Line Road, Princeton, New Jersey 08543 (US). **MENG, Wei**; c/o Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534 (US). **BRIGANCE, Robert Paul**; c/o Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534 (US). **DEVASTHALE, Pratik**; c/o Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534 (US).

[Continued on next page]

(54) Title: ARYL DIHYDROPYRIDINONE AND PIPERIDINONE AS MGAT2 INHIBITORS



(57) Abstract: The present invention provides compounds of Formula (I), or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.



(74) **Agents:** SUN, Jing G. et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))